Revier Therapeutics, a new Heidelberg-based biotechnology company, has officially launched its operations with the closing of a €6 million seed financing round. The investment was led by the KHAN Technology Transfer Fund II and will advance the company's mission to develop disease-modifying therapies. The firm is focused on creating novel treatments for patients suffering from cardiometabolic diseases with significant unmet needs.
Addressing Unmet Medical Needs
According to CEO Prof. Eva van Rooij, millions of patients with conditions like heart failure with preserved ejection fraction (HFpEF) still lack targeted treatments. The company believes the next generation of medicines must address the underlying disease-driving biology to be truly effective. Revier's mission is to translate its scientific potential into a pipeline of novel therapies to provide impactful, long-term solutions.
A Novel Therapeutic Approach
Revier Therapeutics is pioneering a new approach by selectively targeting class IIa histone deacetylases (HDACs), enzymes that play a key role in severe diseases. Scientific founder Prof. Johannes Backs noted that previous HDAC inhibitors were too broad, resulting in dose-limiting side effects. Revier's first-in-class small molecules are designed with greater precision to avoid these past limitations and improve patient outcomes.
The company's orally available small molecules are engineered to inhibit only the pathogenic enzymatic activity of class IIa HDACs. This precision preserves the essential biological functions of these enzymes and avoids the issues associated with canonical HDAC inhibition. This specific mode of action is intended to deliver therapeutic effectiveness while maintaining a more favorable safety profile for patients.
Strategic Investment and Vision
The financing round saw participation from High-Tech Gründerfonds (HTGF), VORNvc, and private investors through Revier Invest Heidelberg. Michael Hamacher of lead investor KHAN Technology Transfer Fund II expressed confidence in Revier's differentiated strategy and exceptional leadership team. He highlighted the company's potential to unlock the therapeutic promise of HDAC biology and reshape the standard of care.
The newly acquired €6 million in capital will be instrumental in advancing the company's preclinical cardiometabolic pipeline. These funds are earmarked to support its lead program in HFpEF and a second program in atherosclerotic cardiovascular disease (ASCVD). The investment will also facilitate the build-out of Revier's operational, scientific, and clinical functions as it grows.
Leadership and Regional Support
The company has assembled a leadership team of renowned experts in cardiovascular science, drug discovery, and biotechnology. This team includes Prof. Eva van Rooij as CEO and Prof. Johannes Backs as Scientific Founder, alongside other key executives. Their collective expertise provides a strong foundation for the company's ambitious drug discovery and clinical development goals.
Revier's launch also received significant backing from a coalition of regional stakeholders and investors led by business developer Daniel Stern. This local support highlights the strategic importance of biotechnology to the Heidelberg area and the state of Baden-Württemberg. It underscores a strong community commitment to fostering innovation within the local life sciences sector.
With its successful €6 million seed financing and a highly specific scientific platform, Revier Therapeutics is well-positioned to make significant strides. The company's focus on developing disease-modifying therapies for complex cardiometabolic conditions offers new hope for patients with limited options. This launch marks a promising new chapter in the pursuit of more effective and safer cardiovascular treatments.